Clinical Trials Browser

Phase EARLY_PHASE1 × sugemalimab × 90 days × Clear all

NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Phase EARLY_PHASE1 Recruiting

Pleural Effusion, Malignant